during an average follow-up of 25 months , there were statistically significant reductions in total mortality ( 26 % ) , cardiovascular mortality ( 26 % ) , arteriosclerotic heart disease ( 27 % ) , sudden death ( 28 % ) and coronary incidence ( definite nonfatal reinfarction plus coronary heart disease mortality ) ( 23 % ) .
C0007226
cardiovascular
C0010054
coronary